Enhertu
Fam-Trastuzumab Deruxtecan-Nxki
- Strength
- 100mg
- Manufacturer
- AstraZeneca Pharma
- Availability
- Available to source
Fam-Trastuzumab Deruxtecan-Nxki 100mg — Injection, 1's Vial
Need assistance?
Our multilingual healthcare support team can help with availability, shipping and ordering.
Chat on WhatsApp
Scan for WeChat
Enhertu uses and dosage
Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) is a prescription medicine used to treat certain types of HER2+ metastatic breast cancer and HER2- low metastatic breast cancer, HER2- mutant metastatic lung cancer, HER2+ advanced stomach cancer, or esophagus cancer. ENHERTU is FDA approved for the treatment of several types of cancer. Trastuzumab deruxtecan is used to treat tumors which are involved with the HER2 protein. This medicine is a combination of a monoclonal antibody and a topoisomerase inhibitor. Trastuzumab deruxtecan binds to the HER2 cancer cells and prevents them from splitting and expanding. Enhertu manufactured by AstraZeneca Pharma Ltd. in India. Trastuzumab Deruxtecan has to take by slow injection into a vein by a health care professional, usually once every week or once every 3 weeks. The first injection is given over at least 90 minutes.
Indications
Enhertu side effects
The most common side effects of Trastuzumab deruxtecan are: Diarrhea, dizziness, stomach/abdominal pain, constipation, nausea, vomiting, mouth sores, dry mouth, loss of appetite, tiredness, hair loss, nose bleeds, or headache
- Originator brand
- Enhertu by Daiichi Sankyo
- Made by
- AstraZeneca Pharma
This information is provided for reference only and is not medical advice. Always consult a qualified healthcare professional.
